Tagged with GEN

Pharma André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution; how unlike many of their competitors, they are a gene editing company at the core and why the idea of…

Pharma Marcyrl grew 40 percent and jumped from 15th to 9th place in the Egyptian market in 2014. With growth remaining strong, the board explains the keys to success for doing business in an unstable environment, and shares their plans for expansion, including a nearly completed hormonal facility. Marcyrl has expanded…

Pharma OrganoPharma’s founder and chairman Dr. Mowfak Sakr explains how he founded his company to try and provide the 40 million people in Egypt who lack healthcare insurance of any kind with safe, effective, and affordable medicines, and shares his vision for expanding the company internationally. Dr. Sakr, what is OrganoPharma…

Pharma Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics of the Italian market that make it especially promising to Celgene. Mr. Frega, to start off, Imnovid, Celgene’s newest oral treatment…

Pharma Click here to read more articles and interviews from Peru, and to download the latest free pharma report on the country. 

Pharma Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees emerging and the market environment for generics companies in Italy today. When we last spoke in 2009, you told us…

Pharma Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete  initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help to tackle the current difficulties in accessing the Dutch market, while implementing new innovative pricing models such as pay for benefit.…

Pharma Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager Jasper van Grunsven explains the challenges of preparing for the upcoming year in the midst of structural changes to the…

Pharma Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system does not capture the benefits that the next generation of gene therapy products deliver over time, transforming chronic diseases into…

Pharma Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from biometric identities to cut costs and improve funds allocation, and how GenKey aims to become the “Google of digital identity”…

Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…

Pharma Pharmed Healthcare is the only Egyptian company to hold a License from the innovator to produce generic sofosbuvir, but faces competition from at least ten different companies in the market. Given your experience in trying to combat the hepatitis C virus (HCV), which is an epidemic in Egypt, what are some…